KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders (2023 - 2025)

Biocryst Pharmaceuticals' Net Income towards Common Stockholders history spans 9 years, with the latest figure at $245.8 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 1017.5% year-over-year to $245.8 million; the TTM value through Dec 2025 reached $263.9 million, up 396.87%, while the annual FY2025 figure was $263.9 million, 396.87% up from the prior year.
  • Net Income towards Common Stockholders reached $245.8 million in Q4 2025 per BCRX's latest filing, up from $12.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $245.8 million in Q4 2025 to a low of -$170.4 million in Q4 2023.
  • Average Net Income towards Common Stockholders over 3 years is $506000.0, with a median of -$12.7 million recorded in 2024.
  • Peak YoY movement for Net Income towards Common Stockholders: skyrocketed 84.28% in 2024, then soared 1017.5% in 2025.
  • A 3-year view of Net Income towards Common Stockholders shows it stood at -$170.4 million in 2023, then surged by 84.28% to -$26.8 million in 2024, then skyrocketed by 1017.5% to $245.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Net Income towards Common Stockholders are $245.8 million (Q4 2025), $12.9 million (Q3 2025), and $5.1 million (Q2 2025).